Flagship Pioneering-backed Expedition Medicines launched with an AI‑driven platform that analyzes proteome chemistry to design small molecules for targets considered undruggable. The company disclosed an R&D alliance with Pfizer and aims to apply its platform to cancer targets and other challenging protein classes. Expedition’s approach emphasizes learning binding rules across biology to expand small‑molecule discovery into new target classes. Early industry partnerships and Flagship’s track record signal potential for rapid translational work, though wet‑lab proof points and candidate nominations will determine industry uptake. The startup joins a growing wave of AI‑native drug companies seeking to bridge computational design with scalable chemistry and development partnerships.